Moderate to Severe Plaque Psoriasis Co-primary Endpoints Data | TREMFYA® (guselkumab) HCP

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
TREMFYA® HAS SET THE BAR AT PASI 90 AS A PRIMARY ENDPOINT IN PHASE 3 TRIALS

7 Out of 10 Patients Achieved PASI 90 at Week 16 After Just 3 Injections in TREMFYA® Clinical Trials1,2

VOYAGE 1

Results at Week 16

VOYAGE 2: CO-PRIMARY ENDPOINTS AT WEEK 16 vs PLACEBO (GLOBAL ANALYSIS)1,3‬‬‬‬‬‬‬‬

*P<0.001 vs placebo.

Based on the results of an analysis of 101 global sites from VOYAGE 1 and 115 global ‭sites from VOYAGE 2 (including North American ‭sites [ie, United States and Canada]).‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418‑431.